Le Clorennec, Christophe
Lazrek, Yassamine
Dubreuil, Olivier
Sampaio, Carla
Larbouret, Christel
Lanotte, Romain
Poul, Marie-Alix
Barret, Jean-Marc
Prost, Jean-François
Pèlegrin, André
Chardès, Thierry http://orcid.org/0000-0002-1836-7439
Funding for this research was provided by:
Agence nationale de la Recherche (ANR-10-LABX-53-01)
Fonds Unique Interministeriel (FUI UmAbHER3 F120402M)
Article History
Received: 7 May 2019
Accepted: 5 August 2019
First Online: 23 August 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: OD, JMB, and JFP are employed by GamaMabs Pharma. AP, CL and TC are inventors in the WO2012/156532 patent “Anti-human HER3 and uses thereof”, the WO2015/067986 patent “Neuregulin allosteric anti-HER3 antibody”, and the WO2016/177664 patent “Low-fucose anti-human HER3 antibodies and uses thereof”. OD, JMB and JFP are inventors in the WO2016/177664 patent “Low-fucose anti-human HER3 antibodies and uses thereof”. The other authors declare no conflict of interest.